Announcements
- Ultimovacs ASA announces revised terms of the employee share option program
- Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
- Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
- Ultimovacs ASA – Annual General Meeting held on April 18, 2024
- Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
- Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
- Ultimovacs – Invitation to Business Update on April 17, 2024
- Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
More ▼
Key statistics
On Tuesday, Ultimovacs ASA (7UM:DUS) closed at 0.661, 34.90% above the 52 week low of 0.49 set on Mar 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.661 |
---|---|
High | 0.661 |
Low | 0.661 |
Bid | -- |
Offer | -- |
Previous close | 0.659 |
Average volume | 0.00 |
---|---|
Shares outstanding | 34.41m |
Free float | 23.37m |
P/E (TTM) | -- |
Market cap | 271.12m NOK |
EPS (TTM) | -5.17 NOK |
Data delayed at least 15 minutes, as of Jun 25 2024 07:12 BST.
More ▼